Alaska Air Posts Loss After Hit From Boeing Door Plug Blowout
By Helena Smolak
Alaska Air Group posted a first-quarter net loss after it took a hit from the blowout of a Boeing jet door plug during a flight in January.
The airline on Thursday reported a net loss of $132 million, or $1.05 a share, compared with a net loss of $142 million, or $1.11 a share, a year earlier.
On an adjusted basis, the company's loss widened to $116 million, or $0.92 a share, compared with a loss of $79 million, or $0.62 a share, last year. Alaska Air previously said that it expected a first-quarter adjusted loss of $1.15 a share to $1.05 a share.
The airline said the flight incident in January and the Boeing 737-9 MAX grounding that extended into February had significantly weighed on operations in the first quarter. Boeing handed the carrier $162 million in cash compensation for financial damages.
This quarter, the company is forecasting earnings per share between $2.20 and $2.40. For the full year, it expects earnings per share of $3.25 to $5.25.
Write to Helena Smolak at helena.smolak@wsj.com
(END) Dow Jones Newswires
April 18, 2024 06:34 ET (10:34 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Small-Cap and Value Stocks Are Undervalued
-
Why We Expect the Job Market’s Slowdown to Renew in 2024
-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Amazon Earnings: AWS Growth Accelerates and Profit Margins Improve
-
SiriusXM Earnings: Decent Results With Plan for Technology and Content Investment to Drive Growth
-
Coca-Cola Earnings: Solid Volume On Innovation and Digital Engagement
-
Is Berkshire Hathaway a Buy Before the Annual Meeting?
-
Investment Opportunities in the Drug Distribution Industry
-
Why the End of Quantitative Tightening Matters
-
Eli Lilly Earnings: Strong Weight-Loss Drug Sales Expand Margins
-
After Earnings, Is Meta Stock a Buy, a Sell, or Fairly Valued?